Athersys to Present at 25th Annual Piper Jaffray Healthcare Conference

        Print
| Source: Athersys, Inc.

CLEVELAND, Nov. 25, 2013 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that the Company will present at the 25th Annual Piper Jaffray Healthcare Conference taking place at The New York Palace on December 3rd and 4th , 2013 in New York City.

William (B.J.) Lehmann, President and Chief Operating Officer, will present on Wednesday, December 4, 2013 at 4:00 p.m. Eastern Standard Time.

During the presentation, material information concerning the Company, its operations, strategies and prospects may be discussed. To listen to the live audio webcast of the presentation during the event, please visit: www.athersys.com. A replay of the webcast will be available for 30 days after the initial presentation.

About Athersys

Athersys is a clinical stage biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product platform for disease indications in the cardiovascular, neurological, inflammatory and immune disease areas. The Company currently has several clinical stage programs involving MultiStem, including for treating inflammatory bowel disease, ischemic stroke, damage caused by myocardial infarction, and for the prevention of graft-versus-host disease. Athersys has also developed a diverse portfolio that includes other technologies and product development opportunities, and has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions in the United States and Europe to further develop its platform and products. More information is available at www.athersys.com.

The Athersys, Inc. logo is available at: http://www.globenewswire.com/newsroom/prs/?pkgid=4548

William (B.J.) Lehmann, J.D.
President and Chief Operating Officer
Tel: (216) 431-9900


Investor Relations:
Lisa M. Wilson
In-Site Communications
Tel: (917) 543-9932